Equities Analysts Issue Forecasts for MNPR FY2026 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Monopar Therapeutics in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee now expects that the company will post earnings of $0.70 per share for the year, up from their prior forecast of $0.12. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2027 earnings at $2.10 EPS and FY2028 earnings at $3.04 EPS.

A number of other analysts have also weighed in on the company. Rodman & Renshaw initiated coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 price objective on the stock. Piper Sandler initiated coverage on Monopar Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $72.00 price objective on the stock.

Monopar Therapeutics Trading Up 5.4 %

Monopar Therapeutics stock opened at $41.46 on Friday. Monopar Therapeutics has a twelve month low of $1.54 and a twelve month high of $41.94. The stock’s fifty day simple moving average is $24.19 and its 200-day simple moving average is $12.34. The firm has a market capitalization of $252.91 million, a P/E ratio of -21.05 and a beta of 1.23.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan bought 1,550 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average price of $16.25 per share, with a total value of $25,187.50. Following the completion of the acquisition, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at $25,187.50. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 34.90% of the stock is currently owned by corporate insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.